Objective:To assess the efficacy, safety and economy of antimicrobial agents in patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD), and to rationalize use of antimicrobial agents. Methods:Clinical data of hospitalized patients with AECOPD from July 2017 to December 2018 in a municipal secondary hospital were retrospectively investigated, the category, cost and use length of antimicrobial drugs were statistically analyzed, and the rationality of antimicrobial drug use was determined by combining case data. Results:A total of 662 patients with AECOPD were included in this study, with a general accuracy rate of 94.4%. On average, the rates were 82.1% in accuracy+correct dosage, 66.9% in accuracy+correct dosage+timing of administration, and 54.8% in accuracy+correct dosage+timing of administration+duration of administration, respectively. The top 3 drugs ranked by defined daily doses(DDDs) were B-lactam enzyme inhibitors, cephalosporins, and quinolones, of which ceftriaxone sodium and tazobactam sodium for injection showed an average treatment duration(ATD) of>10 d, and drug utilization index(DUI) of>1.0, while piperacillin sodium and sulbactam for injection had a DUI far less than 1.0, and ceftazidime B/A for injection ranged from 1 to 2 in all three semi-annual periods. Conclusion:The use of antibacterial drugs for AECOPD in this hospital is basically reasonable, and the number of antibacterial drugs is increasing but the utilization rate of antibacterial drugs is decreasing on the yearly basis. There is a steadily good synchronization of sales amount with DDDs, in line with the characteristics of economic and practical drugs. Admittedly, more works are needed to rationally use antibiotic drugs, especially in dosage and length of administration.
 URA M,TANAKA H,TAKAHASHI K,et al.Value of fractional exhaled nitric oxide after using a beta2 bronchodilator in the differential diagnosis of bronchial asthma and chronic obstructive pulmonary disease[J].Rinsho Byori,2016,64(2):127-132.
 BLASI F,CESANA G,CONTI S,et al.The clinical and economic impact of exacerbations of chronic obstructive pulmonary disease:a cohort of hospitalized patients[J].PLoS One,2014,9(6):1-8.
 DIMOPOULOS G,TSIODRAS S,LERIKOU M,et al.Viral profile of COPD exacerbations according to patients[J].Open Respiratory Medicine Journal,2015,9(1):1-8.
 HAUG J B,REIKVAM A.WHO defined daily doses versus hospital-adjusted defined daily doses:impact on results of antibiotic use surveillance[J].J Antimicrob Chemother,2013,68(12):2940-2947.